divarasib

Start here

Synthesis

Roche has reported phase III results for divarasib, a next-generation KRAS G12C inhibitor, in previously treated KRAS G12C-mutant non-small cell lung cancer. The head-to-head trial randomized 338 patients against an approved first-generation KRAS G12C inhibitor, and divarasib delivered a median overall survival of 17.7 months versus 12.0 months, a 44% reduction in the risk of death. The reported response rate was 58.4%. The trial is described as the first phase III head-to-head study of a next-generation KRAS G12C inhibitor against an approved first-generation one. Roche announced the results on October 25.

Written by a model from the reports · updated 3 hours ago

Latest developmentOct 26 09:40

Roche reported phase III head-to-head results for divarasib in KRAS G12C lung cancer on October 25.

Coverage timeline

Follow the coverage to see the different angles.

Oct 26

09:40
mp.weixin.qq.comPick
Roche divarasib head-to-head in KRAS-mutant lung cancer: 338 patients, response rate 58.4%
Roche reported phase III head-to-head results for divarasib on October 25. The trial randomized 338 previously treated KRAS G12C lung cancer patients; median overall survival was 17.7 months versus 12.0 months, with a 44% reduction in risk of death. The source describes it as the first phase III head-to-head study of a next-generation KRAS G12C inhibitor against an approved first-generation inhibitor, and the headline gives a response rate of 58.4%.
05:04
x.com
Not all KRAS G12C inhibitors are equal. Once approved, divarasib could be our preferred option after first line, and the real question is how quickly we move it to the first line.
04:06
x.com
#ESMO26
02:44
x.com
Divarasib beats adagrasib and sotorasib in the 2nd line treatment of KRAS G12C mutated NSCLC. This sets a new standard for now, but I’m hopeful that this is just the first of many
00:12
x.com
Exciting!
00:08
x.com
The last dance for KRAS inhibitors. Divarasib . Nice discussion. Systemic cross over should be reconsiderd when PFS is the primar end point. It will be intr to see future data f

Oct 25

Heat trend for this story

Heat now 79·Peak in the comparable set 95 (Oct 26 06:00)·Change over 24h in the comparable set –·Participants now 12

Participants counted12

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.